Navigation Links
AstraZeneca's Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008
Date:10/9/2008

Ramped Up Marketing Efforts and FDA Activity Drive Growth at Top Brand.com

Sites

RESTON, Va., Oct. 9 /PRNewswire-FirstCall/ -- comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today released a study of the top pharmaceutical brand Web sites in Q2 2008. The study revealed that purplepill.com, AstraZeneca's Web site for its heartburn treatment Nexium, generated the most site traffic in Q2 2008 with more than 1 million unique visitors, up 55 percent from year ago. Also showing substantial growth versus last year was diabetes drug Actos, ranking second with 855,000 unique visitors. Insomnia medication Ambien CR, ranked third with 756,000 unique visitors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080115/COMSCORELOGO)

"AstraZeneca has aggressively marketed Nexium this year, running approximately twice as much online display advertising in Q2 as either of its major competitors, Prevacid and Aciphex," said John Mangano, senior director, comScore Pharmaceutical Marketing Solutions. "This additional marketing muscle appears to have helped generate strong site visitation, a very important marketing step in the competitive pharmaceutical industry."

Top 10 Pharmaceutical Brand Web Sites by Unique Visitors

Q2 2008 vs. Q2 2007

Total U.S. -- Home/Work/University Locations

Source: comScore, Inc.

Unique Visitors (000)

Web Site Q2 2007 Q2 2008 Percent Change

Nexium (purplepill.com) 659 1,021 55 %

Actos (actos.com) 34 855 2399 %

Ambien CR (ambiencr.com) 1,949 756 -61 %

Gardasil (gardasil.com) 912 722 -21 %

Lexapro (lexapro.com) 530 549 3 %

Veramyst (veramyst.com) N/A 538 N/A

Januvia (januvia.com) 118 507 329 %

Lyrica (lyrica.com) 368 501 36 %

Topamax (topamax.com) 361 498 38 %

Seroquel (seroquel.com) 359 447 24 %

Some highlights from the study include:

-- Takeda Pharmaceuticals substantially increased marketing for the Actos brand beginning in the third quarter of 2007, helping build actos.com into the second most visited site in the category in Q2 2008 versus year ago.

-- Merck's diabetes treatment Januvia increased marketing activity beginning in the second half of last year, resulting in a nearly 330-percent increase in visitors to januvia.com.

-- Pfizer has ramped up marketing and public relations efforts for Lyrica since the third quarter of 2007, when the product received FDA approval to be marketed for the treatment of fibromyalgia. The site, lyrica.com, has seen a 36-percent increase in unique visitors.

-- With a number of migraine treatments nearing patent expirations, the makers of popular migraine treatment Topomax launched a heavy online display ad campaign to bolster awareness, resulting in a 38-percent increase in Q2 2008 versus year ago.

-- Merck's highly publicized HPV vaccine Gardasil was approved by the FDA in the second quarter of 2006. Although the number of site visitors has declined 21 percent during the past year since the company's initial marketing and public relations push, the site still ranks among the top 5 most visited sites with 722,000 visitors.

These industry insights along with an analysis of other relevant online health trends will be presented during a complimentary webinar conducted by comScore and ePharma Summit entitled, Internet Trends and Usage in 2008 and Beyond, on Thursday, October 16 from 2 to 3 p.m. EDT.

To register for the webinar visit https://www1.gotomeeting.com/register/831770879 and mention priority code G1P1406W2COM.

For more information on comScore Pharmaceutical solutions, please visit: http://www.comscore.com/solutions/info_req.asp?industry=pharma.

About comScore

comScore, Inc. (NASDAQ: SCOR) is a global leader in measuring the digital world and preferred source of digital marketing intelligence. For more information, please visit http://www.comscore.com/boilerplate.


'/>"/>
SOURCE comScore, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The MOTHERS Act: Thalidomide Revisited?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health ... this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the ... of Population Health Management/Patient Engagement Solutions. , MAP was selected as a ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Cremations recently surpassed ... Funeral Directors Association, this trend is expected to continue with over 70% of Americans ... a growing demand for new innovations that enable families to celebrate the life of ...
(Date:7/26/2017)... Miami, FL (PRWEB) , ... July 26, 2017 , ... ... caps that treat hereditary hair loss. The new Flexible Fitting Design offers a more ... of Capillus, LLC is delighted with the improvements to the home-use laser therapy caps ...
(Date:7/26/2017)... Madison, WI (PRWEB) , ... July 26, 2017 ... ... launch of Talent Management Solutions as part of their continued efforts to provide ... retain, and develop the best IT resources and build dynamic, high-performing teams to ...
(Date:7/26/2017)... PA (PRWEB) , ... July 26, 2017 , ... “We ... said Dr. Ahmed Mauassra, from San Jose, Calif., “so we invented the MAGNETIC/ LOCK ... the bracket portion of orthodontic braces. In doing so, it offers an effective alternative ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/21/2017)... 21, 2017 Did you know that PhRMA member companies ... that combined spending on brand medicines, generics and the supply chain ... accounting for just half of this (7 percent)? Or that ... the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: